The Emerging Role of Psilocybin and MDMA in the Treatment of Mental Illness

The extracted text indicates this article is a narrative review of available clinical and preclinical literature regarding psilocybin and MDMA. The authors organise the review around pharmacology and putative mechanisms, safety and tolerability data, and evidence across psychiatric indications such as major depressive disorder (MDD), anxiety related to advanced cancer, obsessive–compulsive disorder (OCD) and post-traumatic stress disorder (PTSD). The extraction does not report a formal systematic search strategy, databases searched, date ranges, inclusion/exclusion criteria, or a prespecified risk-of-bias assessment method. Instead, the paper synthesises published clinical trials (including open‑label pilot studies, double‑blind placebo‑controlled pilot trials, and Phase II dose‑response trials), neuroimaging studies, preclinical data, and observational findings from recreational‑use cohorts. A table listing active and/or recruiting trials is referenced in the text but detailed selection methods for studies included in that table are not described in the extracted material.

Mechanistic summaries: For psilocybin, the review reports that oral psilocybin is rapidly dephosphorylated to psilocin, which acts primarily as an agonist at 5‑HT2A receptors and shows affinity for several other serotonin subtypes (5‑HT1, 5‑HT4, 5‑HT5, 5‑HT6, 5‑HT7) and dopamine receptors (D1, D3). The authors describe a hypothesised cascade in which 5‑HT2A activation increases extracellular glutamate in the prefrontal cortex, modulates AMPA and NMDA receptor signalling, and upregulates neurotrophic factors (for example brain‑derived neurotrophic factor), a pathway plausibly linked to antidepressant and anxiolytic effects. The review notes converging imaging evidence that psilocybin and S‑ketamine may affect similar prefrontal and limbic networks. For MDMA, the paper emphasises that the drug is absorbed rapidly, reaches peak plasma concentrations in about 2–3 hours, and principally inhibits monoamine reuptake with highest affinity for the serotonin transporter (SERT). MDMA’s psychophysiological profile—euphoria, increased sociability and reduced fear—may assist psychotherapy for trauma‑related disorders by facilitating access to traumatic memories. The authors also report preclinical and human data suggesting MDMA can lead to marked cerebrospinal serotonin depletion and reduced SERT expression in some contexts. Safety and tolerability: Psilocybin is presented as low in chronic toxicity, moderate in acute toxicity, and with little evidence of physical dependence or withdrawal in clinical settings; nevertheless, dose‑dependent adverse effects (panic reactions, persistent perceptual disturbances or long‑lasting psychiatric symptoms) have been reported and warrant controlled clinical administration. MDMA trials report common short‑term effects such as loss of appetite, nausea, dizziness, tiredness, headaches, transient increases in blood pressure and heart rate, and perceptual or cognitive changes. Preclinical signals of serotonergic axonal damage, sympathomimetic risks (hyperthermia, arrhythmia, malignant hypertension) and epidemiological data indicating higher mortality with MDMA than with some other stimulants are noted; the authors therefore stress the need for careful monitoring in clinical use. Disorder‑specific clinical findings: For major depressive disorder and treatment‑resistant depression (TRD), early open‑label and pilot trials of psilocybin reported rapid reductions in depressive symptoms: one pilot trial found symptom reductions at one week and at three months, and Roseman et al. (n=20) reported improvements on the QIDS‑SR16 following two sessions (10 mg and 25 mg). Carhart‑Harris and colleagues found that decreased amygdala cerebral blood flow correlated with mood improvement in TRD, and a post‑hoc analysis linked a ‘‘mystical’’ high‑dose experience with better outcomes; in one imaging sample 47% met response criteria at five weeks. Psilocybin for anxiety related to advanced cancer produced significant reductions in trait anxiety at three months (p=0.03) and reduced depressive symptoms at six months (p=0.03) in a small double‑blind placebo‑controlled pilot (n=12). Ross et al. (n=29) reported sustained antidepressant and anxiolytic effects 6.5 months after 0.3 mg/kg psilocybin‑assisted psychotherapy. For OCD, Moreno et al. (n=9) administered up to four single doses ranging from sub‑hallucinogenic to hallucinogenic and observed transient symptomatic reductions within 24 hours (p=0.046) with no clear dose–response. The authors note that repeat‑dose data and larger samples are lacking. Regarding PTSD, multiple studies of MDMA‑assisted psychotherapy are summarised. Early pilot data (Mithoefer et al.) showed significant symptom improvements with no serious adverse effects and persistence of benefit on long‑term follow‑up. A small randomised trial in six women showed psychological and physiological safety at 50–75 mg doses; a Phase II dose‑response trial in veterans and first responders (total n=26) compared 30 mg, 75 mg and 125 mg and reported significant PTSD symptom reduction at one month in the 75 mg and 125 mg groups (p=0.001) with effects sustained at 12 months. Ot'alora et al. (n=28) found larger CAPS‑IV reductions in active dose groups (100 mg and 125 mg) versus low dose (40 mg), and reported that 76% of participants no longer met PTSD criteria at 12 months. A pooled follow‑up of participants receiving at least one active MDMA dose (n=57) reported significant reductions in post‑traumatic growth (PTG) measures and PTSD symptoms (both p<0.001). Limitations of the evidence base: The review repeatedly notes that many clinical studies were small, proof‑of‑concept and often open‑label, limiting generalisability. Dose‑response relationships, long‑term safety in representative clinical populations, and mechanistic links between receptor activity and clinical outcomes remain incompletely characterised in the extracted text.

Gill and colleagues interpret the assembled evidence as indicating that psilocybin and MDMA hold promise as novel therapeutic approaches for several psychiatric disorders, particularly TRD and PTSD, where rapid and durable responses have been observed in early trials. They emphasise a potentially important clinical advantage for psychedelics: a ‘‘single‑dose’’ or limited‑session model that could serve as monotherapy or as a powerful adjunct to psychotherapy, possibly reducing the burden of chronic daily pharmacotherapy. Mechanistically, the authors underscore distinct but complementary rationales: psilocybin’s 5‑HT2A agonism and downstream glutamatergic and neurotrophic effects may underlie antidepressant and anxiolytic responses, while MDMA’s SERT‑mediated monoamine elevation and prosocial, fear‑reducing subjective effects may enhance processing of traumatic memories. At the same time, the review cautions that safety considerations—particularly MDMA’s sympathomimetic profile and preclinical signals of serotonergic neurotoxicity—require controlled administration and thorough risk–benefit assessment. The authors acknowledge key limitations in the current literature reported in the extraction: small sample sizes, a predominance of open‑label designs, heterogeneous dosing and psychotherapy protocols, limited long‑term safety data, and inadequate study of comorbidities and cognitive outcomes. They therefore call for additional randomized, double‑blind, placebo‑controlled dose‑response trials in clinically representative populations, systematic assessment of adverse effects in specific subpopulations (for example TRD patients), and mechanistic studies that link receptor‑level action to clinical outcomes. Finally, the review recommends caution in translating recreational‑use data to therapeutic contexts and stresses that administration should occur within closed clinical settings with appropriate monitoring.